NMR structure and dynamics of recombinant wild type and mutated jerdostatin, a selective inhibitor of integrin α 1β 1

Proteins: Structure, Function and Bioinformatics

Volumn 79, Issue 8, 2011, Pages 2530-2542

  Carbajo, Rodrigo J ^a   Sanz, Libia ^b   Mosulén, Silvia ^a   Pérez, Alicia ^b   Marcinkiewicz, Cezary ^c   Pineda Lucena, Antonio ^a   Calvete, Juan J ^b  

^a CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^b INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Disintegrin jerdostatin; Integrin antagonist; NMR structure; Protein dynamics; Recombinant protein; Snake venom toxin

Indexed keywords

ARGININE; DISINTEGRIN; FIBRINOGEN; FIBRONECTIN; JERDOSTATIN; LAMININ; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 1; VERY LATE ACTIVATION ANTIGEN 2; VITRONECTIN;

ARTICLE; BINDING AFFINITY; CARBON NUCLEAR MAGNETIC RESONANCE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; MOLECULAR DYNAMICS; NITROGEN NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTON NUCLEAR MAGNETIC RESONANCE; RECEPTOR BINDING; THERMODYNAMICS; WILD TYPE;

ANIMALS; DISINTEGRINS; INTEGRIN ALPHA1BETA1; MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN BINDING; PROTEIN CONFORMATION; THERMODYNAMICS; VIPERIDAE;

EID: 79960075193     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.23076     Document Type: Article

References (59)

1. Carmeliet, P. Angiogenesis in life, disease & medicine. Nature 2005; 438: 932-936.
2. Cao Y. Angiogenesis: what can it offer for future medicine? Exp Cell Res 2010; 316: 1304-1308.
3. Folkman J. Angiogenesis. Annu Rev Med 2006; 57: 1-18.
4. Twardowski P, Gradishar WJ. Clinical trials of antiangiogenic agents. Curr Opin Oncol 1997; 9: 584-589.
5. Folkman J. Tumorangiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
6. Serini G, Valdembri D, Bussolino F. Integrins and angiogenesis: a sticky business. Exp Cell Res 2006; 312: 651-658.
7. Mettouchi A, Meneguzzi G. Distinct roles of beta1 integrins during angiogenesis. Eur J Cell Biol 2006; 85: 243-247.
8. Miranti CK, Brugge JS. Sensing the environment: a historical perspective on integrin signal transduction. Nat Cell Biol 2002; 4: 83-90.
9. Alghisi GC, Ruegg C. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium 2006; 13: 113-135.
10. Akalu A, Cretu A, Brooks PC. Targeting integrins for the control of tumour angiogenesis. Expert Opin Investig Drugs 2005; 14: 1475-1486.
11. D'Andrea LD, Del Gatto A, Pedone C, Benedetti E. Peptide-based molecules in angiogenesis. Chem Biol Drug Des 2006; 67: 115-126.
12. Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010; 60: 222-243.
13. Sanz L, Bazaa A, Marrakchi N, Pérez A, Chenik M, Bel Lasfer Z, El Ayeb M, Calvete JJ. Molecular cloning of disintegrins from Cerastes vipera and Macrovipera lebetina transmediterranea venom gland cDNA libraries: insight into the evolution of the snake venom integrin-inhibition system. Biochem J 2006; 395: 385-392.
14. Juárez P, Comas I, González-Candelas F, Calvete JJ. Evolution of snake venom disintegrins by positive Darwinian selection. Mol Biol Evol 2008; 25: 2391-2407.
15. Swenson S, Ramu S, Markland FS. Anti-angiogenesis and RGD-containing snake venom disintegrins. Curr Pharm Des 2005; 13: 2860-2871.
16. 1 integrin. Curr Pharm Des 2007; 13: 2853-2859.
17. 1 integrin in vitro and angiogenesis in vivo. Cancer Res 2003; 63: 2020-2023.
18. Ma D, Gao L, An S, Song Y, Wu J, Xu X, Lai R. A horsefly saliva antigen 5-like protein containing RTS motif is an angiogenesis inhibitor. Toxicon 2010; 55: 45-51.
19. Monleón D, Moreno-Murciano MP, Kovacs H, Marcinkiewicz C, Calvete JJ, Celda B. Concerted motions of the integrin-binding loop and the C-terminal tail of the non-RGD disintegrin obtustatin. J Biol Chem 2003; 278: 45570-45576.
20. 1 integrin. FEBS Lett 2004; 577: 478-482.
21. 1 integrin. J Biol Chem 2005; 280: 40714-40722.
22. Bauer M, Sun Y, Degenhardt C, Kozikowski B. Assignment of all four disulfide bridges in echistatin. J Protein Chem 1993; 12: 759-764.
23. Marcinkiewicz C, Calvete JJ, Marcinkiewicz MM, Raida M, Vijay-Kumar S, Huang Z, Lobb RR, Niewiarowski S. EC3, a novel heterodimeric disintegrin from Echis carinatus venom, inhibits α4 and α5 integrins in an RGD-independent manner. J Biol Chem 1999; 274: 12468-12473.
24. Moreno-Murciano MP, Monleón D, Marcinkiewicz C, Calvete JJ, Celda B. NMR solution structure of the non-RGD disintegrin obtustatin. J Mol Biol 2003; 329: 135-145.
25. Kwan AH, Mobli M, Gooley PR, King GF, Mackay JP. Macromolecular NMR spectroscopy for the non-spectroscopist. FEBS J 2011; 78: 687-703.
26. Burgen ASV, Roberts GCK, Feeney J. Binding of flexible ligands to macromolecules. Nature 1975; 253: 753-755.
27. Calvete JJ, Marcinkiewicz C, Monleón D, Esteve V, Celda B, Juárez P, Sanz L. Snake venom disintegrins: evolution of structure and function. Toxicon 2005; 45: 1063-1074.
28. 1 integrin. Biochem J 2009; 417: 95-101.
29. García De La Torre J, Huertas ML, Carrasco B. HYDRONMR: prediction of NMR relaxation of globular proteins from atomic-level structures and hydrodynamic calculations. J Magn Reson 2000; 147: 138-146.
30. Bernadó P, García De La Torre J. Interpretation of N-15 NMR relaxation data of globular proteins using hydrodynamic calculations with HYDRONMR. J Biomol NMR 2002; 23: 139-150.
31. Hall JB, Fushman D. Characterization of the overall and local dynamics of a protein with intermediate rotational anisotropy: differentiating between conformational exchange and anisotropic diffusion in the B3 domain of protein G. J Biomol NMR 2003; 27: 261-275.
32. Dosset P, Hus JC, Blackledge M, Marion D. Efficient analysis of macromolecular rotational diffusion from heteronuclear relaxation data. J Biomol NMR 2000; 16: 23-28.
33. Lipari G, Szabo A. Model-free approach to the interpretation of nuclear magnetic resonance relaxation in macromolecules. 1. Theory and range of validity. J Am Chem Soc 1982; 104: 4546-4559.
34. Luginbühl P, Pervushin KV, Iwai H, Wüthrich K. Anisotropic molecular rotational diffusion in N-15 spin relaxation studies of protein mobility. Biochemistry 1997; 36: 7305-7312.
35. Calvete JJ. Brief history and molecular determinants of snake venom disintegrin evolution. In: Kini RM, Clemetson K, Markland F, McLane MA, Morita T, editors. Toxins and hemostasis: from bench to bedside. Dordrecht, NL: Springer; 2010. pp 285-300.
36. Marcinkiewicz C. Functional characteristics of snake venom disintegrins: potential therapeutic implications. Curr Pharm Des 2005; 11: 815-827.
37. Arnaout MA, Goodman SL, Xiong JP. Structure and mechanics of integrin-based cell adhesion. Curr Opin Cell Biol 2007; 19: 495-507.
38. Monleón D, Esteve V, Kovacs H, Calvete JJ, Celda B. Conformation and concerted dynamics of the integrin-binding site and the C-terminal region of echistatin revealed by homonuclear NMR. Biochem J 2005; 387: 57-66.
39. Mittermaier A, Kay LE. New tools provide new insights in NMR studies of protein dynamics. Science 2006; 312: 224-228.
40. Henzler-Wildman KA, Lei M, Thai V, Kerns SJ, Karplus M, Kern D. A hierarchy of timescales in protein dynamics is linked to enzyme catalysis. Nature 2007; 450: 913-916.
41. Palmer AG. A topical issue: NMR investigations of molecular dynamics. J Biomol NMR 2009; 45: 1-4.
42. Williams RJP. NMR studies of mobility within protein structure. Eur J Biochem 1989; 183: 479-497.
43. Wand AJ. Dynamic activation of protein function: a view emerging from NMR spectroscopy. Nat Struct Mol Biol 2001; 8: 926-931.
44. Kern D, Zuiderweg ERP. The role of dynamics in allosteric regulation. Curr Opin Struct Biol 2003; 13: 748-757.
45. Boehr DD, Nussinov R, Wright PE. The role of dynamic conformational ensembles in biomolecular recognition. Nat Chem Biol 2009; 5: 789-796.
46. Adler M, Lazarus RA, Dennis MS, Wagner G. Solution structure of kistrin, a potent platelet aggregation inhibitor and GPIIb-IIIa antagonist. Science 1991; 253: 445-448.
47. Senn H, Klaus W. The nuclear magnetic resonance solution structure of flavoridin, an antagonist of the platelet GPIIb-IIIa receptor. J Mol Biol 1993; 232: 907-925.
48. 1H NMR spectroscopy and simulated annealing calculations. Int J Pept Protein Res 1996; 48: 220-228.
49. Chen Y, Suri AK, Kominos D, Sanyal G, Naylor AM, Pitzenberger SM, Garsky VM, Levy RM, Baum J. Three-dimensional structure of echistatin and dynamics of the active site. J Biomol NMR 1994; 4: 307-324.
50. Goddard TD, Kneller DG. SPARSKY 3. San Francisco, University of California; 2005.
51. Berjanskii MV, Wishart DS. Application of the random coil index to studying protein flexibility. J Biomol NMR 2008; 40: 31-48.
52. Grzesiek S, Stahl SJ, Wingfield PT, Bax A. The CD4 determinant for downregulation by HIV-1 Nef directly binds to Nef. Mapping of the Nef binding surface by NMR. Biochemistry 1996; 35: 10256-10261.
53. Brunger AT. Vrsion 1.2 of the Crystallography and NMR system. Nat Protoc 2007; 2: 2728-2733.
54. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 1993; 26: 283-291.
55. Koradi R, Billeter M, Wüthrich K. MOLMOL: a program for display and analysis of macromolecular structures. J Mol Graphics 1996; 14: 51-55.
56. DeLano WL. The PyMOL molecular graphics system. San Carlos, CA: DeLano Scientifics. Available from
57. Farrow NA, Muhandiram R, Singer AU, Pascal SM, Kay CM, Gish G, Shoelson SE, Pawson T, Forman-Kay JD, Kay LE. Backbone dynamics of a free and a phosphopeptide-complexed Src homology-2 domain studied by N-15 NMR relaxation. Biochemistry 1994; 33: 5984-6003.
58. 15 relaxation parameters. J Biomol NMR 2001; 20: 149-165.
59. Pantoja-Uceda D, Arolas JL, García P, López-Hernández E, Padró D, Avilés FX, Blanco FJ. The NMR structure and dynamics of the two-domain tick carboxypeptidase inhibitor reveal flexibility in its free form & stiffness upon binding to human carboxypeptidase B. Biochemistry 2008; 47: 7066-7078.